Table 1: Sales by Geographic Area - 2023 1 Table 1a: Sales by Geographic Area - 2022 2 Table 2: Condensed Consolidated Statement of Earnings - 2023 3 Table 2a: Condensed Consolidated Statement of Earnings - 2022 4 Table 3: Non-GAAP Adjusted Net Earnings - 2023 5 Table 3a: Non-GAAP Adjusted Net Earnings - 2022 6 Table 4: Non-GAAP Adjusted Operational Sales Growth - 2023 7 Table 4a: Non-GAAP Adjusted Operational Sales Growth - 2022 8 Table 5: Non-GAAP IBT by Segment - Q1 2023 9 Table 5a: Non-GAAP IBT by Segment - Q2 2023 10 Table 5b: Non-GAAP IBT by Segment - Q1 2022 11 Table 5c: Non-GAAP IBT by Segment - Q2 2022 12 Table 5d: Non-GAAP IBT by Segment - Q3 2022 13 Table 5e: Non-GAAP IBT by Segment - Q4 2022 14 Table 6: Non-GAAP P&L Reconciliation - 2023 15 Table 6a: Non-GAAP P&L Reconciliation - 2022 16 August 30, 2023 Restated Financial Disclosures Table of Contents -- 1 of 17 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) 2023 2022 Total Operations Currency Sales to customers by geographic area U.S. 10,782 $ 9,857 9.4 % 9.4 - Europe 5,590 5,341 4.7 9.4 (4.7) Western Hemisphere excluding U.S. 1,076 998 7.8 15.5 (7.7) Asia-Pacific, Africa 3,446 3,644 (5.4) 3.1 (8.5) International 10,112 9,983 1.3 7.7 (6.4) Worldwide 20,894 $ 19,840 5.3 % 8.5 (3.2) (Unaudited; Dollars in Millions) 2023 2022 Total Operations Currency Sales to customers by geographic area U.S. 11,657 $ 10,510 10.9 % 10.9 - Europe 5,131 5,355 (4.2) (5.2) 1.0 Western Hemisphere excluding U.S. 1,136 1,027 10.7 16.8 (6.2) Asia-Pacific, Africa 3,595 3,323 8.2 14.3 (6.1) International 9,862 9,705 1.6 3.8 (2.2) Worldwide 21,519 $ 20,215 6.5 % 7.5 (1.0) (Unaudited; Dollars in Millions) 2023 2022 Total Operations Currency Sales to customers by geographic area U.S. 22,439 $ 20,367 10.2 % 10.2 - Europe 10,721 10,696 0.2 2.1 (1.9) Western Hemisphere excluding U.S. 2,212 2,025 9.3 16.2 (6.9) Asia-Pacific, Africa 7,041 6,967 1.1 8.5 (7.4) International 19,974 19,688 1.5 5.8 (4.3) Worldwide 42,413 $ 40,055 5.9 % 8.0 (2.1) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely Percent Change FIRST QUARTER Percent Change SECOND QUARTER Percent Change SIX MONTHS -- 2 of 17 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) 2022 2021 Total Operations Currency Sales to customers by geographic area U.S. 9,857 $ 9,500 3.8 % 3.8 - Europe 5,341 4,727 13.0 21.2 (8.2) Western Hemisphere excluding U.S. 998 968 3.0 4.2 (1.2) Asia-Pacific, Africa 3,644 3,485 4.6 8.3 (3.7) International 9,983 9,180 8.7 14.5 (5.8) Worldwide 19,840 $ 18,680 6.2 % 9.1 (2.9) (Unaudited; Dollars in Millions) 2022 2021 Total Operations Currency Sales to customers by geographic area U.S. 10,510 $ 10,168 3.4 % 3.4 - Europe 5,355 4,936 8.5 22.1 (13.6) Western Hemisphere excluding U.S. 1,027 933 10.2 13.2 (3.0) Asia-Pacific, Africa 3,323 3,421 (2.9) 6.2 (9.1) International 9,705 9,290 4.5 15.4 (10.9) Worldwide 20,215 $ 19,458 3.9 % 9.1 (5.2) (Unaudited; Dollars in Millions) 2022 2021 Total Operations Currency Sales to customers by geographic area U.S. 10,794 $ 10,338 4.4 % 4.4 - Europe 4,844 4,833 0.2 16.1 (15.9) Western Hemisphere excluding U.S. 1,059 1,019 3.9 9.1 (5.2) Asia-Pacific, Africa 3,299 3,336 (1.1) 11.4 (12.5) International 9,202 9,188 0.1 13.6 (13.5) Worldwide 19,996 $ 19,526 2.4 % 8.7 (6.3) (Unaudited; Dollars in Millions) 2022 2021 Total Operations Currency Sales to customers by geographic area U.S. 10,820 $ 10,634 1.7 % 1.7 - Europe 5,124 6,099 (16.0) (6.3) (9.7) Western Hemisphere excluding U.S. 1,024 1,007 1.7 8.3 (6.6) Asia-Pacific, Africa 2,971 3,336 (10.9) 3.0 (13.9) International 9,119 10,442 (12.7) (1.9) (10.8) Worldwide 19,939 $ 21,076 (5.4) % (0.1) (5.3) (Unaudited; Dollars in Millions) 2022 2021 Total Operations Currency Sales to customers by geographic area U.S. 41,981 $ 40,640 3.3 % 3.3 - Europe 20,664 20,595 0.3 12.1 (11.8) Western Hemisphere excluding U.S. 4,108 3,927 4.6 8.7 (4.1) Asia-Pacific, Africa 13,237 13,578 (2.5) 7.2 (9.7) International 38,009 38,100 (0.2) 10.0 (10.2) Worldwide 79,990 $ 78,740 1.6 % 6.5 (4.9) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely THIRD QUARTER FIRST QUARTER Percent Change SECOND QUARTER Percent Change Percent Change FOURTH QUARTER Percent Change TWELVE MONTHS Percent Change -- 3 of 17 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Amount to Sales Amount to Sales Amount to Sales Sales to customers 20,894 $ 100.0 21,519 $ 100.0 42,413 $ 100.0 Cost of products sold 6,687 32.0 6,462 30.0 13,149 31.0 Gross Profit 14,207 68.0 15,057 70.0 29,264 69.0 Selling, marketing and administrative expenses 4,906 23.5 5,396 25.1 10,302 24.3 Research and development expense 3,455 16.6 3,703 17.2 7,158 16.9 In-process research and development Impairments 49 0.2 - - 49 0.1 Interest income (198) (0.9) (326) (1.5) (524) (1.2) Interest expense, net of portion capitalized 212 1.0 217 1.0 429 1.0 Other (income) expense, net 6,940 33.2 (384) (1.8) 6,556 15.5 Restructuring 130 0.6 145 0.7 275 0.6 Earnings/(loss) before provision for taxes on income (1,287) (6.2) 6,306 29.3 5,019 11.8 Provision for/(Benefit from) taxes on income (796) (3.9) 930 4.3 134 0.3 Net earnings/(loss) from Continuing Operations (491) $ (2.3) 5,376 $ 25.0 4,885 $ 11.5 Net earnings/(loss) from Discontinued Operations, net of tax 423 (232) 191 Net earnings/(loss) (68) $ 5,144 $ 5,076 $ Net Earnings (loss) per Share (Diluted) from Continuing Operations (0.19) $ 2.05 $ 1.86 $ Net Earnings (loss) per Share (Diluted) from Discontinued Operations 0.16 $ (0.09) $ 0.07 $ Average shares outstanding (Diluted) 2,605.5 * 2,625.7 2,630.7 *Basic Shares used as in an overall loss position Effective tax rate from Continuing Operations 61.8 % 14.7 % 2.7 % Adjusted earnings from continuing operations before provision for taxes and net earnings (1) Earnings before provision for taxes on income from continuing operations 7,536 $ 36.1 8,005 $ 37.2 15,541 $ 36.6 Net earnings from continuing operations 6,340 $ 30.3 6,730 $ 31.3 13,070 $ 30.8 Net earnings per share (Diluted) from continuing operations 2.41 $ 2.56 $ 4.97 $ Average shares outstanding (Diluted) 2,634.3 2,625.7 2,630.7 Effective tax rate from continuing operations 15.9 % 15.9 % 15.9 % (1) See Reconciliation of Non-GAAP Financial Measures. 2023 Q1 Q2 SIX MONTHS -- 4 of 17 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Percent Percent Percent Amount to Sales Amount to Sales Amount to Sales Amount to Sales Amount to Sales Amount to Sales Sales to customers 19,840 $ 100.0 20,215 $ 100.0 40,055 $ 100.0 19,996 $ 100.0 19,939 $ 100.0 79,990 $ 100.0 Cost of products sold 6,018 30.3 6,322 31.3 12,340 30.8 6,172 30.9 6,084 30.5 24,596 30.7 Gross Profit 13,822 69.7 13,893 68.7 27,715 69.2 13,824 69.1 13,855 69.5 55,394 69.3 Selling, marketing and administrative expenses 4,812 24.3 5,120 25.3 9,932 24.8 4,975 24.9 5,339 26.8 20,246 25.3 Research and development expense 3,355 16.9 3,585 17.7 6,940 17.3 3,485 17.4 3,710 18.6 14,135 17.7 In-process research and development Impairments 610 3.1 - - 610 1.5 - - 173 0.8 783 1.0 Interest income (22) (0.1) (64) (0.3) (86) (0.2) (150) (0.8) (254) (1.3) (490) (0.6) Interest expense, net of portion capitalized 10 0.1 38 0.2 48 0.1 51 0.3 177 0.9 276 0.3 Other (income) expense, net (210) (1.1) (1) 0.0 (211) (0.5) 226 1.1 795 4.0 810 1.0 Restructuring 64 0.3 71 0.4 135 0.4 65 0.3 75 0.4 275 0.4 Earnings before provision for taxes on income 5,203 26.2 5,144 25.4 10,347 25.8 5,172 25.9 3,840 19.3 19,359 24.2 Provision for taxes on income 632 3.2 882 4.3 1,514 3.7 862 4.3 613 3.1 2,989 3.7 Net earnings from Continuing Operations 4,571 23.0 4,262 $ 21.1 8,833 $ 22.1 4,310 $ 21.6 3,227 $ 16.2 16,370 $ 20.5 Net earnings from Discontinued Operations, net of tax 578 552 1,130 148 293 1,571 Net earnings 5,149 $ 4,814 $ 9,963 $ 4,458 $ 3,520 $ 17,941 $ Net Earnings per Share (Diluted) from Continuing Operations 1.71 $ 1.60 $ 3.31 $ 1.62 $ 1.22 $ 6.14 $ Net Earnings per Share (Diluted) from Discontinued Operations 0.22 $ 0.20 $ 0.42 $ 0.06 $ 0.11 $ 0.59 $ Average shares outstanding (Diluted) 2,666.5 2,667.9 2,669.2 2,661.3 2,650.1 2,663.9 Effective tax rate from Continuing Operations 12.1 % 17.1 % 14.6 % 16.7 % 16.0 % 15.4 % Adjusted earnings from continuing operations before provision for taxes and net earnings (1) Earnings before provision for taxes on income from continuing operations 7,349 $ 37.0 7,082 $ 35.0 14,431 $ 36.0 7,060 $ 35.3 6,482 $ 32.5 27,973 $ 35.0 Net earnings from continuing operations 6,388 $ 32.2 6,038 $ 29.9 12,426 $ 31.0 5,938 $ 29.7 5,432 $ 27.2 23,796 $ 29.7 Net earnings per share (Diluted) from continuing operations 2.40 $ 2.26 $ 4.66 $ 2.23 $ 2.05 $ 8.93 $ Average shares outstanding (Diluted) 2,666.5 2,667.9 2,669.2 2,661.3 2,650.1 2,663.9 Effective tax rate from continuing operations 13.1 % 14.7 % 13.9 % 15.9 % 16.2 % 14.9 % (1) See Reconciliation of Non-GAAP Financial Measures. 2022 Q1 Q2 SIX MONTHS Q3 Q4 FULL YEAR -- 5 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) Q1 Q2 SIX MONTHS Net Earnings/(loss) from Continuing Operations, after tax - as reported ($491) $5,376 $4,885 Pre-tax Adjustments Intangible Asset Amortization expense 1,122 1,130 2,252 Litigation related 6,900 137 7,037 IPR&D impairments 49 0 49 Restructuring related 130 145 275 Acquisition, integration and divestiture related 42 38 80 (Gains)/losses on securities 72 (1) 71 Medical Device Regulation 64 85 149 COVID-19 Vaccine related costs 444 165 609 Tax Adjustments Tax impact on special item adjustments (1,980) (307) (2,287) Consumer Health separation tax related costs 11 (17) (6) Tax legislation and other tax related (23) (21) (44) Adjusted Net Earnings from continuing operations, after tax $6,340 $6,730 $13,070 Average shares outstanding (Diluted) 2,634.3 2,625.7 2,630.7 Adjusted net earnings per share from continuing operations (Diluted) $2.41 $2.56 $4.97 2023 -- 6 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) Q1 Q2 Q3 Q4 FULL YEAR Net Earnings from Continuing Operations, after tax - as reported $4,571 $4,262 $4,310 $3,227 $16,370 Pre-tax Adjustments Intangible Asset Amortization expense 1,014 995 958 977 3,944 Litigation related 0 385 219 262 866 IPR&D impairments 610 0 0 173 783 Restructuring related 58 103 92 119 372 Acquisition, integration and divestiture related 0 0 0 196 196 (Gains)/losses on securities 411 109 164 6 690 Medical Device Regulation 60 70 78 88 296 COVID-19 Vaccine related costs 0 276 377 821 1,474 Other (7) 0 0 0 (7) Tax Adjustments Tax impact on special item adjustments (346) (242) (312) (394) (1,294) Consumer Health separation tax related costs 96 2 (36) 4 66 Tax legislation and other tax related (79) 78 88 (47) 40 Adjusted Net Earnings from continuing operations, after tax $6,388 $6,038 $5,938 $5,432 $23,796 Average shares outstanding (Diluted) 2,666.5 2,667.9 2,661.3 2,650.1 2,663.9 Adjusted net earnings per share from continuing operations (Diluted) $2.40 $2.26 $2.23 $2.05 $8.93 2022 -- 7 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Q2 SIX MONTHS WW As Reported 5.3% 6.5% 5.9% U.S. 9.4% 10.9% 10.2% International 1.3% 1.6% 1.5% WW Currency (3.2) (1.0) (2.1) U.S. - - - International (6.4) (2.2) (4.3) WW Operational 8.5% 7.5% 8.0% U.S. 9.4% 10.9% 10.2% International 7.7% 3.8% 5.8% Abiomed (1.6) (1.6) (1.6) U.S. (2.7) (2.6) (2.6) International (0.6) (0.6) (0.6) All Other Acquisitions and Divestitures 0.0 0.1 0.0 U.S. 0.0 0.0 0.0 International 0.1 0.2 0.2 WW Adjusted Operational 6.9% 6.0% 6.4% U.S. 6.7% 8.3% 7.6% International 7.2% 3.4% 5.4% Note: Percentages are based on actual, non-rounded figures and may not sum Adjusted Operational Sales Growth 2023 ACTUAL vs. 2022 ACTUAL Total Enterprise Q1 -- 8 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Q2 SIX MONTHS Q3 NINE MONTHS Q4 TWELVE MONTHS WW As Reported 6.2% 3.9% 5.0% 2.4% 4.1% (5.4)% 1.6% U.S. 3.8% 3.4% 3.6% 4.4% 3.8% 1.7% 3.3% International 8.7% 4.5% 6.6% 0.1% 4.5% (12.7)% (0.2)% WW Currency (2.9) (5.2) (4.1) (6.3) (4.8) (5.3) (4.9) U.S. - - - - - - - International (5.8) (10.9) (8.4) (13.5) (10.0) (10.8) (10.2) WW Operational 9.1% 9.1% 9.1% 8.7% 8.9% (0.1)% 6.5% U.S. 3.8% 3.4% 3.6% 4.4% 3.8% 1.7% 3.3% International 14.5% 15.4% 15.0% 13.6% 14.5% (1.9)% 10.0% Abiomed (0.1) U.S. (0.3) International 0.0 All Other Acquisitions and Divestitures 0.0 0.1 0.1 0.1 0.1 0.1 0.0 U.S. 0.0 0.1 0.0 0.1 0.0 0.1 0.0 International 0.0 0.1 0.1 0.1 0.1 0.1 0.1 WW Adjusted Operational 9.1% 9.2% 9.2% 8.8% 9.0% (0.1)% 6.5% U.S. 3.8% 3.5% 3.6% 4.5% 3.8% 1.5% 3.3% International 14.5% 15.5% 15.1% 13.7% 14.6% (1.8)% 10.1% Adjusted Operational Sales Growth 2022 ACTUAL vs. 2021 ACTUAL Note: Percentages are based on actual, non-rounded figures and may not sum Total Enterprise Q1 -- 9 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures Pharmaceutical MedTech Unallocated Reported Income Before Tax by Segment from Continuing Operations $ 4,402 1,409 (7,098) (1,287) % to Sales 32.8% 18.8% -34.0% -6.2% Intangible asset amortization expense 739 383 - 1,122 In-process research and development Impairments - 49 - 49 Litigation Related - - 6,900 6,900 Loss/(gain) on securities 38 34 - 72 Restructuring related 130 - - 130 Acquisition, integration and divestiture related - 42 - 42 Medical Device Regulation - 64 - 64 COVID-19 Vaccine related costs 444 - - 444 Adjusted Income Before Tax by Segment from Continuing Operations $ 5,753 1,981 (198) 7,536 % to Sales 42.9% 26.5% -0.9% 36.1% Q1 2023 - Income Before Tax by Segment from Continuing Operations Dollars in Millions Worldwide Total -- 10 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures Pharmaceutical MedTech Unallocated Reported Income Before Tax by Segment from Continuing Operations $ 4,812 1,671 (177) 6,306 % to Sales 35.0% 21.5% -0.8% 29.3% Intangible asset amortization expense 748 382 - 1,130 In-process research and development Impairments - - - - Litigation Related (93) 60 170 137 Loss/(gain) on securities 38 (39) - (1) Restructuring related 145 - - 145 Acquisition, integration and divestiture related - 38 - 38 Medical Device Regulation - 85 - 85 COVID-19 Vaccine related costs 165 - - 165 Adjusted Income Before Tax by Segment from Continuing Operations $ 5,815 2,197 (7) 8,005 % to Sales 42.3% 28.2% 0.0% 37.2% Pharmaceutical MedTech Unallocated Reported Income Before Tax by Segment from Continuing Operations $ 9,214 3,080 (7,275) 5,019 % to Sales 33.9% 20.2% -17.2% 11.8% Intangible asset amortization expense 1,487 765 - 2,252 In-process research and development Impairments - 49 - 49 Litigation Related (93) 60 7,070 7,037 Loss/(gain) on securities 76 (5) - 71 Restructuring related 275 - - 275 Acquisition, integration and divestiture related - 80 - 80 Medical Device Regulation - 149 - 149 COVID-19 Vaccine related costs 609 - - 609 Adjusted Income Before Tax by Segment from Continuing Operations $ 11,568 4,178 (205) 15,541 % to Sales 42.6% 27.4% -0.5% 36.6% Worldwide Total Q2 2023 QTD - Income Before Tax by Segment from Continuing Operations Dollars in Millions Worldwide Total Q2 2023 YTD - Income Before Tax by Segment from Continuing Operations Dollars in Millions -- 11 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures Pharmaceutical MedTech Unallocated Reported Income Before Tax by Segment from Continuing Operations $ 3,873 1,441 (111) 5,203 % to Sales 30.1% 20.7% -0.6% 26.2% Intangible asset amortization expense 760 254 - 1,014 In-process research and development Impairments 610 - - 610 Loss/(gain) on securities 394 17 - 411 Restructuring related (14) 72 - 58 Medical Device Regulation - 60 - 60 Other - - (7) (7) Adjusted Income Before Tax by Segment from Continuing Operations $ 5,623 1,844 (118) 7,349 % to Sales 43.7% 26.5% -0.6% 37.0% Q1 2022 - Income Before Tax by Segment from Continuing Operations Dollars in Millions Worldwide Total -- 12 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures Pharmaceutical MedTech Unallocated Reported Income Before Tax by Segment from Continuing Operations $ 4,365 1,110 (331) 5,144 % to Sales 32.8% 16.1% -1.6% 25.4% Intangible asset amortization expense 736 259 - 995 Litigation Related 21 264 100 385 Loss/(gain) on securities 102 7 - 109 Restructuring related 23 80 - 103 Medical Device Regulation - 70 - 70 COVID-19 Vaccine related costs 276 - - 276 Adjusted Income Before Tax by Segment from Continuing Operations $ 5,523 1,790 (231) 7,082 % to Sales 41.5% 25.9% -1.1% 35.0% Pharmaceutical MedTech Unallocated Reported Income Before Tax by Segment from Continuing Operations $ 8,238 2,551 (442) 10,347 % to Sales 31.5% 18.4% -1.1% 25.8% Intangible asset amortization expense 1,496 513 - 2,009 In-process research and development Impairments 610 - - 610 Litigation Related 21 264 100 385 Loss/(gain) on securities 496 24 - 520 Restructuring related 9 152 - 161 Medical Device Regulation - 130 - 130 COVID-19 Vaccine related costs 276 - - 276 Other - - (7) (7) Adjusted Income Before Tax by Segment from Continuing Operations $ 11,146 3,634 (349) 14,431 % to Sales 42.6% 26.2% -0.9% 36.0% Worldwide Total Q2 2022 QTD - Income Before Tax by Segment from Continuing Operations Dollars in Millions Worldwide Total Q2 2022 YTD - Income Before Tax by Segment from Continuing Operations Dollars in Millions -- 13 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures Pharmaceutical MedTech Unallocated Reported Income Before Tax by Segment from Continuing Operations $ 4,186 1,090 (104) 5,172 % to Sales 31.7% 16.1% -0.5% 25.9% Intangible asset amortization expense 698 260 - 958 Litigation Related 7 212 - 219 Loss/(gain) on securities 177 (13) - 164 Restructuring related 23 69 - 92 Medical Device Regulation - 78 - 78 COVID-19 Vaccine related costs 377 - - 377 Adjusted Income Before Tax by Segment from Continuing Operations $ 5,468 1,696 (104) 7,060 % to Sales 41.4% 25.0% -0.5% 35.3% Pharmaceutical MedTech Unallocated Reported Income Before Tax by Segment from Continuing Operations $ 12,424 3,641 (546) 15,519 % to Sales 31.5% 17.6% -0.9% 25.8% Intangible asset amortization expense 2,194 773 - 2,967 In-process research and development Impairments 610 - - 610 Litigation Related 28 476 100 604 Loss/(gain) on securities 673 11 - 684 Restructuring related 32 221 - 253 Medical Device Regulation - 208 - 208 COVID-19 Vaccine related costs 653 - - 653 Other - - (7) (7) Adjusted Income Before Tax by Segment from Continuing Operations $ 16,614 5,330 (453) 21,491 % to Sales 42.2% 25.8% -0.8% 35.8% Worldwide Total Q3 2022 QTD - Income Before Tax by Segment from Continuing Operations Dollars in Millions Worldwide Total Q3 2022 YTD - Income Before Tax by Segment from Continuing Operations Dollars in Millions -- 14 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures Pharmaceutical MedTech Unallocated Reported Income Before Tax by Segment from Continuing Operations $ 3,223 806 (189) 3,840 % to Sales 24.5% 11.9% -0.9% 19.3% Intangible asset amortization expense 717 260 - 977 In-process research and development Impairments 173 - - 173 Litigation Related 76 136 50 262 Loss/(gain) on securities 23 (17) - 6 Restructuring related 31 88 - 119 Acquisition, integration and divestiture related (104) 300 - 196 Medical Device Regulation - 88 - 88 COVID-19 Vaccine related costs 821 - - 821 Adjusted Income Before Tax by Segment from Continuing Operations $ 4,960 1,661 (139) 6,482 % to Sales 37.7% 24.5% -0.7% 32.5% Pharmaceutical MedTech Unallocated Reported Income Before Tax by Segment from Continuing Operations $ 15,647 4,447 (735) 19,359 % to Sales 29.8% 16.2% -0.9% 24.2% Intangible asset amortization expense 2,911 1,033 - 3,944 In-process research and development Impairments 783 - - 783 Litigation Related 104 612 150 866 Loss/(gain) on securities 696 (6) - 690 Restructuring related 63 309 - 372 Acquisition, integration and divestiture related (104) 300 - 196 Medical Device Regulation - 296 - 296 COVID-19 Vaccine related costs 1,474 - - 1,474 Other - - (7) (7) Adjusted Income Before Tax by Segment from Continuing Operations $ 21,574 6,991 (592) 27,973 % to Sales 41.0% 25.5% -0.7% 35.0% Worldwide Total Q4 2022 QTD - Income Before Tax by Segment from Continuing Operations Dollars in Millions Worldwide Total Q4 2022 YTD - Income Before Tax by Segment from Continuing Operations Dollars in Millions -- 15 of 17 -- Quarter to Date First Quarter April 2, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related Medical Device Regulation First Quarter April 2, 2023 Non-GAAP Cost of products sold 6,687 $ (1,118) - (23) (206) 5,340 Selling, marketing and admin expenses 4,906 (7) 4,899 Research and development expense 3,455 (16) (34) (16) 3,389 Other (Income) / Expense 6,940 (4) (6,900) - (26) (72) (222) (284) In-process research and development Impairments 49 (49) - Interest (Income) / Expense 14 14 Restructuring 130 (130) - Provision for/(Benefit from) taxes on income (796) 177 1,622 11 32 5 16 12 105 (11) 23 1,196 Net Earnings/(Loss) from Continuing Operations (491) 945 5,278 38 98 37 56 52 339 11 (23) 6,340 Quarter to Date Second Quarter July 2, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Second Quarter July 2, 2023 Non-GAAP Cost of products sold 6,462 $ (1,130) - (34) 38 - - 5,336 Selling, marketing and admin expenses 5,396 (8) 5,388 Research and development expense 3,703 - (44) (46) 3,613 Other (Income) / Expense (384) - (137) - (38) 1 (156) - (714) In-process research and development Impairments - - - Interest (Income)/Expense (109) (109) Restructuring 145 (145) - Provision for taxes on income 930 177 29 - 37 12 (1) 15 38 17 21 1,275 Net Earnings from Continuing Operations 5,376 953 108 - 108 26 - 71 126 (17) (21) 6,730 Year to Date Six Months July 2, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Six Months July 2, 2023 Non-GAAP Cost of products sold 13,149 $ (2,248) - (57) (168) 10,676 Selling, marketing and admin expenses 10,302 (15) 10,287 Research and development expense 7,158 (16) (78) (62) 7,002 Other (Income) / Expense 6,556 (4) (7,037) - (64) (71) (378) - (998) In-process research and development Impairments 49 (49) - - - Interest (Income)/Expense (95) (95) Restructuring 275 (275) - Provision for taxes on income 134 354 1,651 11 69 17 15 27 143 6 44 2,471 Net Earnings from Continuing Operations 4,885 1,898 5,386 38 206 63 56 123 465 (6) (44) 13,070 Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Consumer Health separation tax related costs In-process research and development Impairments (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related Tax legislation and other tax related Consumer Health separation tax related costs In-process research and development Impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related Consumer Health separation tax related costs In-process research and development Impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs -- 16 of 17 -- Quarter to Date First Quarter April 3, 2022 GAAP Intangible asset amortization Litigation related Restructuring related Acquisition, integration and divestiture related Medical Device Regulation Other First Quarter April 3, 2022 Non-GAAP Cost of products sold 6,018 $ (1,014) (14) (22) 4,968 Selling, marketing and admin expenses 4,812 (6) 4,806 Research and development expense 3,355 (32) 3,323 Other (Income) / Expense (210) - - 20 - (411) - 7 (594) In-process research and development Impairments 610 (610) - Restructuring 64 (64) - Provision for taxes on income 632 148 (53) 138 8 - 96 11 - (96) 79 (2) 961 Net Earnings from Continuing Operations 4,571 866 53 472 50 - 315 49 - 96 (79) (5) 6,388 Quarter to Date Second Quarter July 3, 2022 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Second Quarter July 3, 2022 Non-GAAP Cost of products sold 6,322 $ (995) (14) (25) (194) - - - 5,094 Selling, marketing and admin expenses 5,120 (6) 5,114 Research and development expense 3,585 - (39) (110) 3,436 Other (Income) / Expense (1) - (385) (18) - (109) 28 - - (485) In-process research and development Impairments - - - Restructuring 71 (71) - Provision for taxes on income 882 148 (29) - 20 - 25 13 65 (2) (78) - 1,044 Net Earnings from Continuing Operations 4,262 847 414 - 83 - 84 57 211 2 78 - 6,038 Quarter to Date Third Quarter Oct 2, 2022 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Third Quarter Oct 2, 2022 Non-GAAP Cost of products sold 6,172 $ (958) (9) (29) (102) - - - 5,074 Selling, marketing and admin expenses 4,975 (7) 4,968 Research and development expense 3,485 - (42) (80) 3,363 Other (Income) / Expense 226 - (219) (18) - (164) (195) - - (370) In-process research and development Impairments - - - Restructuring 65 (65) - Provision for taxes on income 862 146 (7) - 19 - 43 15 96 36 (88) - 1,122 Net Earnings from Continuing Operations 4,310 812 226 - 73 - 121 63 281 (36) 88 - 5,938 Quarter to Date Fourth Quarter Jan 1, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Fourth Quarter Jan 1, 2023 Non-GAAP Cost of products sold 6,084 $ (977) (25) (33) (160) - - - 4,889 Selling, marketing and admin expenses 5,339 (9) - 5,330 Research and development expense 3,710 - (46) (114) 3,550 Other (Income) / Expense 795 - (262) (19) (196) (6) (547) - - (235) In-process research and development Impairments 173 (173) - Restructuring 75 (75) - Provision for taxes on income 613 148 (36) 40 19 5 2 17 199 (4) 47 - 1,050 Net Earnings from Continuing Operations 3,227 829 298 133 100 191 4 71 622 4 (47) - 5,432 Twelve Months Jan 1, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other Twelve Months Jan 1, 2023 Non-GAAP Cost of products sold 24,596 $ (3,944) (62) (109) (456) 20,025 Selling, marketing and admin expenses 20,246 (28) 20,218 Research and development expense 14,135 - (159) (304) 13,672 Other (Income) / Expense 810 - (866) (35) (196) (690) (714) - 7 (1,684) In-process research and development Impairments 783 (783) - - - Restructuring 275 (275) - Provision for taxes on income 2,989 590 (125) 178 66 5 166 56 360 (66) (40) (2) 4,177 Net Earnings from Continuing Operations 16,370 3,354 991 605 306 191 524 240 1,114 66 40 (5) 23,796 Tax legislation and other tax related Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Consumer Health separation tax related costs In-process research and development Impairments (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related Consumer Health separation tax related costs In-process research and development Impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related Consumer Health separation tax related costs In-process research and development Impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related Consumer Health separation tax related costs In-process research and development Impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Year to Date In-process research and development Impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Consumer Health separation tax related costs Tax legislation and other tax related -- 17 of 17 --